About 8 results found for searched term "JAK-STAT-IN-1" (0.125 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41715 | JAK-STAT-IN-1 | JAK |
| JAK-STAT-IN-1 is a selective JAK-STAT inhibitor. | ||
| M4496 | Linderalactone | Apoptosis |
| Linderalactone is an important sesquiterpene lactone isolated from Radix Linderae. Linderalactone inhibits cancer cell growth by regulating the expression of apoptosis-related proteins and inhibiting the JAK/STAT signaling pathway. Linderalactone also inhibited the proliferation of lung cancer A-549 cells with an IC50 value of 15 µM. | ||
| M10417 | Delphinidin chloride | JAK |
| delfinidolchloride | ||
| Delphinidin (chloride) is an anthocyanidin, a natural plant pigment which can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells. | ||
| M11253 | BD750 | JAK |
| BD750 is an effective immunosuppressant of JAK3/STAT5 and inhibits IL-2-induced JAK3/ STAT5-dependent T cell proliferation with IC50 values of 1.5 μM and 1.1 μM in mice and human T cells, respectively. | ||
| M27897 | SD-1029 | JAK |
| SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation. | ||
| M28058 | MS-1020 | JAK |
| MS-1020 is a potent and ATP-competitive JAK3 inhibitor. MS-1020 inhibits JAK3/STAT signaling and induces apoptosis. MS-1020 promotes cell death. MS-1020 decreases the expression of tyrosine phosphorylated STAT3 levels. MS-1020 has the potential for the research of cancers harboring aberrant JAK3 signaling. | ||
| M30500 | RO8191 | Interferon-α/β/γ |
| CDM-3008; RO4948191 | ||
| RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity. | ||
| M40998 | Compound 25ap | HDAC |
| Compound 25ap is a potent HDAC/JAK/BRD4 triple inhibitor designed based on the novel multi-targeted HDAC inhibitor Fedratinib, which promotes the hyperacetylation of histones and α-microtubulin, hypophosphorylation of STAT3, and down-regulation of LIFR, MCL-1, and c-Myc in MDA-MB-231 cells, and possesses antitumor activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
